{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T04:22:51Z","timestamp":1785558171841,"version":"3.56.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100003769","name":"Eisai","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003769","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s40261-025-01496-x","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T16:58:52Z","timestamp":1760893132000},"page":"957-966","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A Single- and Multiple-Dose Study to Characterize the Pharmacokinetics and Safety of Dotinurad in Healthy Chinese Adults"],"prefix":"10.1007","volume":"45","clinical-trial-number":[{"clinical-trial-number":"nct05278676","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9214-413X","authenticated-orcid":false,"given":"Yun","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9834-6912","authenticated-orcid":false,"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiyuan","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kotomi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rieko","family":"Kokan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8760-1305","authenticated-orcid":false,"given":"Maiko","family":"Nomoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"1496_CR1","unstructured":"Fenando A, Rednam M, Gujarathi R, et al. Gout. [Updated 2024 Feb 12]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan-. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK546606\/. Accessed 3 Dec 2024."},{"key":"1496_CR2","unstructured":"Chinese Society of Endocrinology, Chinese Medical Association. Guideline for the diagnosis and management of hyperuricemia and gout in China (2019). Chinese J Endocrinol Metab. 2020;36:1\u201313. https:\/\/rs.yiigle.com\/cmaid\/1179377. Accessed 3 Dec 2024."},{"key":"1496_CR3","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1038\/s41392-024-01916-y","volume":"9","author":"L Du","year":"2024","unstructured":"Du L, Zong Y, Li H, et al. Hyperuricemia and its related diseases: mechanisms and advances in therapy. Signal Transduct Target Ther. 2024;9:212. https:\/\/doi.org\/10.1038\/s41392-024-01916-y.","journal-title":"Signal Transduct Target Ther"},{"key":"1496_CR4","doi-asserted-by":"publisher","first-page":"1008598","DOI":"10.3389\/fpubh.2022.1008598","volume":"10","author":"B Zhu","year":"2022","unstructured":"Zhu B, Wang Y, Zhou W, et al. Trend dynamics of gout prevalence among the Chinese population, 1990\u20132019: A joinpoint and age-period-cohort analysis. Front Public Health. 2022;10:1008598. https:\/\/doi.org\/10.3389\/fpubh.2022.1008598.","journal-title":"Front Public Health"},{"key":"1496_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.scitotenv.2024.171565","volume":"924","author":"X Zhou","year":"2024","unstructured":"Zhou X, Liu K, Shi C, et al. Estimation of the spatial pattern of gout prevalence across China by wastewater-based epidemiology. Sci Total Environ. 2024;924:171565. https:\/\/doi.org\/10.1016\/j.scitotenv.2024.171565.","journal-title":"Sci Total Environ"},{"key":"1496_CR6","doi-asserted-by":"publisher","unstructured":"Multi-Disciplinary Expert Task Force on Hyperuricemia and Its Related Diseases. [Chinese multi-disciplinary consensus on the diagnosis and treatment of hyperuricemia and its related diseases]. Zhonghua Nei Ke Za Zhi. 2017;56: 235\u201348. https:\/\/doi.org\/10.3760\/cma.j.issn.0578-1426.2017.03.021","DOI":"10.3760\/cma.j.issn.0578-1426.2017.03.021"},{"key":"1496_CR7","doi-asserted-by":"publisher","first-page":"204201882412272","DOI":"10.1177\/20420188241227295","volume":"15","author":"T Han","year":"2024","unstructured":"Han T, Chen W, Qiu X, Wang W. Epidemiology of gout - Global burden of disease research from 1990 to 2019 and future trend predictions. Ther Adv Endocrinol Metab. 2024;15:20420188241227296. https:\/\/doi.org\/10.1177\/20420188241227295.","journal-title":"Ther Adv Endocrinol Metab."},{"key":"1496_CR8","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1038\/s41584-020-0441-1","volume":"16","author":"M Dehlin","year":"2020","unstructured":"Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nat Rev Rheumatol. 2020;16:380\u201390. https:\/\/doi.org\/10.1038\/s41584-020-0441-1.","journal-title":"Nat Rev Rheumatol"},{"key":"1496_CR9","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1186\/s12916-017-0890-9","volume":"15","author":"T Bardin","year":"2017","unstructured":"Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Med. 2017;15:123. https:\/\/doi.org\/10.1186\/s12916-017-0890-9.","journal-title":"BMC Med"},{"key":"1496_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1177\/2047487313514895","volume":"22","author":"LE Clarson","year":"2015","unstructured":"Clarson LE, Chandratre P, Hider SL, et al. Increased cardiovascular mortality associated with gout: a systematic review and meta-analysis. Eur J Prev Cardiol. 2015;22:335\u201343. https:\/\/doi.org\/10.1177\/2047487313514895.","journal-title":"Eur J Prev Cardiol"},{"key":"1496_CR11","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1016\/S0140-6736(18)32158-5","volume":"392","author":"M Doherty","year":"2018","unstructured":"Doherty M, Jenkins W, Richardson H, et al. Efficacy and cost-effectiveness of nurse-led care involving education and engagement of patients and a treat-to-target urate-lowering strategy versus usual care for gout: a randomised controlled trial. Lancet. 2018;392:1403\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(18)32158-5.","journal-title":"Lancet"},{"key":"1496_CR12","unstructured":"KC M, Leslie SW. Uric Acid Nephrolithiasis. [Updated 2023 Oct 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan\u2013. https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK560726\/. Accessed: 3 Dec 2024."},{"key":"1496_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MKH, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51\u20139. https:\/\/doi.org\/10.1053\/j.ajkd.2005.10.006.","journal-title":"Am J Kidney Dis"},{"key":"1496_CR14","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1053\/j.ajkd.2003.12.023","volume":"43","author":"VG Athyros","year":"2004","unstructured":"Athyros VG, Elisaf M, Papageorgiou AA, et al. Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the Greek atorvastatin and coronary-heart-disease evaluation (GREACE) study. Am J Kidney Dis. 2004;43:589\u201399. https:\/\/doi.org\/10.1053\/j.ajkd.2003.12.023.","journal-title":"Am J Kidney Dis"},{"key":"1496_CR15","first-page":"2605","volume-title":"Practice of Internal Medicine","author":"Chen Hao Zhu","year":"2006","unstructured":"Chen Hao Zhu. Practice of Internal Medicine. 12th ed. Beijing: People\u2019s Medical Publishing House; 2006. p. 2605.","edition":"12"},{"key":"1496_CR16","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1080\/14397595.2020.1784556","volume":"31","author":"R Koto","year":"2021","unstructured":"Koto R, Nakajima A, Horiuchi H, Yamanaka H. Real-world treatment of gout and asymptomatic hyperuricemia: a cross-sectional study of Japanese health insurance claims data. Mod Rheumatol. 2021;31:261\u20139. https:\/\/doi.org\/10.1080\/14397595.2020.1784556.","journal-title":"Mod Rheumatol"},{"key":"1496_CR17","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s40801-019-00174-7","volume":"7","author":"C Scavone","year":"2020","unstructured":"Scavone C, Di Mauro C, Ruggiero R, et al. Severe cutaneous adverse drug reactions associated with allopurinol: an analysis of spontaneous reporting system in Southern Italy. Drugs Real World Outcomes. 2020;7:41\u201351. https:\/\/doi.org\/10.1007\/s40801-019-00174-7.","journal-title":"Drugs Real World Outcomes."},{"key":"1496_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.3899\/jrheum.180761","volume":"46","author":"JS Lee","year":"2019","unstructured":"Lee JS, Won J, Kwon OC, et al. Hepatic safety of febuxostat compared with allopurinol in gout patients with fatty liver disease. J Rheumatol. 2019;46:527\u201331. https:\/\/doi.org\/10.3899\/jrheum.180761.","journal-title":"J Rheumatol"},{"key":"1496_CR19","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1056\/NEJMoa1710895","volume":"378","author":"WB White","year":"2018","unstructured":"White WB, Saag KG, Becker MA, et al. Cardiovascular safety of febuxostat or allopurinol in patients with gout. N Engl J Med. 2018;378:1200\u201310. https:\/\/doi.org\/10.1056\/NEJMoa1710895.","journal-title":"N Engl J Med"},{"key":"1496_CR20","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.12998\/wjcc.v7.i13.1717","volume":"7","author":"MY Zhang","year":"2019","unstructured":"Zhang MY, Niu JQ, Wen XY, Jin QL. Liver failure associated with benzbromarone: a case report and review of the literature. World J Clin Cases. 2019;7:1717\u201325. https:\/\/doi.org\/10.12998\/wjcc.v7.i13.1717.","journal-title":"World J Clin Cases."},{"key":"1496_CR21","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.14428","volume":"13","author":"A Iqbal","year":"2021","unstructured":"Iqbal A, Iqbal K, Farid E, et al. Efficacy and safety of dotinurad in hyperuricemic patients with or without gout: a systematic review and meta-analysis of randomized controlled trials. Cureus. 2021;13:e14428. https:\/\/doi.org\/10.7759\/cureus.14428.","journal-title":"Cureus."},{"key":"1496_CR22","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1007\/s10157-020-01849-0","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Dotinurad versus benzbromarone in Japanese hyperuricemic patient with or without gout: a randomized, double-blind, parallel-group, phase 3 study. Clin Exp Nephrol. 2020;24:62\u201370. https:\/\/doi.org\/10.1007\/s10157-020-01849-0.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR23","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1007\/s10157-020-01851-6","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Furuno K, Kanda S. A non-inferiority study of the novel selective urate reabsorption inhibitor dotinurad versus febuxostat in hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:71\u20139. https:\/\/doi.org\/10.1007\/s10157-020-01851-6.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR24","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1124\/jpet.119.259341","volume":"371","author":"T Taniguchi","year":"2019","unstructured":"Taniguchi T, Ashizawa N, Matsumoto K, et al. Pharmacological evaluation of dotinurad, a selective urate reabsorption inhibitor. J Pharmacol Exp Ther. 2019;371:162\u201370. https:\/\/doi.org\/10.1124\/jpet.119.259341.","journal-title":"J Pharmacol Exp Ther"},{"key":"1496_CR25","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.dmpk.2020.03.002","volume":"35","author":"K Omura","year":"2020","unstructured":"Omura K, Miyata K, Kobashi S, et al. Ideal pharmacokinetic profile of dotinurad as a selective urate reabsorption inhibitor. Drug Metab Pharmacokinet. 2020;35:313\u201320. https:\/\/doi.org\/10.1016\/j.dmpk.2020.03.002.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1496_CR26","doi-asserted-by":"publisher","first-page":"1016","DOI":"10.1124\/dmd.120.000251","volume":"49","author":"K Omura","year":"2021","unstructured":"Omura K, Motoki K, Kobashi S, Miyata K, Yamano K, Iwanaga T. Identification of human UDP-glucuronosyltransferase and sulfotransferase as responsible for the metabolism of dotinurad, a novel selective urate reabsorption inhibitor. Drug Metab Dispos. 2021;49:1016\u201324. https:\/\/doi.org\/10.1124\/dmd.120.000251.","journal-title":"Drug Metab Dispos"},{"key":"1496_CR27","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s10157-019-01802-w","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: an exploratory, randomized, multicenter, double-blind, placebo-controlled, parallel-group early phase 2 study. Clin Exp Nephrol. 2020;24:44\u201352. https:\/\/doi.org\/10.1007\/s10157-019-01802-w.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR28","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10157-019-01818-2","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Sano T, Sasaki T, Fushimi M, Ohashi T. Clinical efficacy and safety of dotinurad, a novel selective urate reabsorption inhibitor, in Japanese hyperuricemic patients with or without gout: randomized, multicenter, double-blind, placebo-controlled, parallel-group, confirmatory phase 2 study. Clin Exp Nephrol. 2020;24:53\u201361. https:\/\/doi.org\/10.1007\/s10157-019-01818-2.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR29","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s10157-019-01831-5","volume":"24","author":"T Hosoya","year":"2020","unstructured":"Hosoya T, Fushimi M, Okui D, Sasaki T, Ohashi T. Open-label study of long-term administration of dotinurad in Japanese hyperuricemic patients with or without gout. Clin Exp Nephrol. 2020;24:80\u201391. https:\/\/doi.org\/10.1007\/s10157-019-01831-5.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR30","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.533","volume":"7","author":"K Motoki","year":"2019","unstructured":"Motoki K, Igarashi T, Omura K, et al. Pharmacokinetic\/pharmacodynamic modeling and simulation of dotinurad, a novel uricosuric agent, in healthy volunteers. Pharmacol Res Perspect. 2019;7:e00533. https:\/\/doi.org\/10.1002\/prp2.533.","journal-title":"Pharmacol Res Perspect"},{"key":"1496_CR31","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s10157-019-01836-0","volume":"24","author":"H Nakatani","year":"2020","unstructured":"Nakatani H, Fushimi M, Sasaki T, Okui D, Ohashi T. Clinical pharmacological study of dotinurad administered to male and female elderly or young subjects. Clin Exp Nephrol. 2020;24:8\u201316. https:\/\/doi.org\/10.1007\/s10157-019-01836-0.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/art.43261","author":"J Sun","year":"2025","unstructured":"Sun J, Wang Y, Cheng Y, et al. Efficacy and safety of dotinurad versus febuxostat for the treatment of gout: a randomised, multicentre, double-blind, phase 3 trial in China. Arthritis Rheumatol. 2025. https:\/\/doi.org\/10.1002\/art.43261.","journal-title":"Arthritis Rheumatol"},{"key":"1496_CR33","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12882-024-03535-9","volume":"25","author":"H Amano","year":"2024","unstructured":"Amano H, Kobayashi S, Terawaki H. Dotinurad restores exacerbated kidney dysfunction in hyperuricemic patients with chronic kidney disease. BMC Nephrol. 2024;25:97. https:\/\/doi.org\/10.1186\/s12882-024-03535-9.","journal-title":"BMC Nephrol"},{"key":"1496_CR34","doi-asserted-by":"publisher","first-page":"3233","DOI":"10.2147\/DDDT.S416025","volume":"17","author":"K Yanai","year":"2023","unstructured":"Yanai K, Hirai K, Kaneko S, et al. The efficacy and safety of dotinurad on uric acid and renal function in patients with hyperuricemia and advanced chronic kidney disease: a single center, retrospective analysis. Drug Des Devel Ther. 2023;17:3233\u201348. https:\/\/doi.org\/10.2147\/DDDT.S416025.","journal-title":"Drug Des Devel Ther."},{"key":"1496_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1007\/s10157-023-02419-w","volume":"28","author":"O Kurihara","year":"2024","unstructured":"Kurihara O, Yamada T, Kato K, Miyauchi Y. Efficacy of dotinurad in patients with severe renal dysfunction. Clin Exp Nephrol. 2024;28:208\u201316. https:\/\/doi.org\/10.1007\/s10157-023-02419-w.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR36","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1186\/s40001-023-01208-1","volume":"28","author":"A Tanaka","year":"2023","unstructured":"Tanaka A, Taguchi I, Hisauchi I, et al. Clinical effects of a selective urate reabsorption inhibitor dotinurad in patients with hyperuricemia and treated hypertension: a multicenter, prospective, exploratory study (DIANA). Eur J Med Res. 2023;28:238. https:\/\/doi.org\/10.1186\/s40001-023-01208-1.","journal-title":"Eur J Med Res"},{"key":"1496_CR37","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1136\/annrheumdis-2024-eular.104","volume":"83","author":"J Sun","year":"2024","unstructured":"Sun J, Wang Y, Zhang X, et al. POS0255 A randomized, multicenter, double-blind, phase 3 study comparing efficacy of dotinurad and febuxostat for the treatment of gout in Chinese subjects. Ann Rheum Dis. 2024;83:407\u20138.","journal-title":"Ann Rheum Dis"},{"key":"1496_CR38","unstructured":"Urece tablets 0.5 mg, 1 mg, 2 mg. Japanese package insert. https:\/\/pins.japic.or.jp\/pdf\/newPINS\/00068466.pdf. Accessed: 3 Dec 2024."},{"key":"1496_CR39","unstructured":"China Food and Drug Administration. The Technical Guideline for Chemical Drug Clinical Pharmacokinetic Study. Guidelines Serial No: (H)GCL1-2. March 2005. https:\/\/www.nmpa.gov.cn\/wwwroot\/gsz05106\/07.pdf. Accessed 3 Dec 2024."},{"key":"1496_CR40","unstructured":"Technical Guidelines for Single and Multiple Ascending Dose Pharmacokinetic Studies of Innovative Chemical Drugs. CDE notice No.58, 2021. https:\/\/www.ydcdei.org.cn\/hotspecial\/show\/739475329336487936. Accessed 9 Jan 2025."},{"key":"1496_CR41","doi-asserted-by":"publisher","first-page":"9","DOI":"10.2133\/dmpk.dmpk-11-rv-111","volume":"27","author":"K Kurose","year":"2012","unstructured":"Kurose K, Sugiyama E, Saito Y. Population differences in major functional polymorphisms of pharmacokinetics\/pharmacodynamics-related genes in Eastern Asians and Europeans: implications in the clinical trials for novel drug development. Drug Metab Pharmacokinet. 2012;27:9\u201354. https:\/\/doi.org\/10.2133\/dmpk.dmpk-11-rv-111.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1496_CR42","doi-asserted-by":"publisher","first-page":"232","DOI":"10.3349\/ymj.2014.55.1.232","volume":"55","author":"JY Kim","year":"2014","unstructured":"Kim JY, Cheong HS, Park BL, et al. Comprehensive variant screening of the UGT gene family. Yonsei Med J. 2014;55:232\u20139. https:\/\/doi.org\/10.3349\/ymj.2014.55.1.232.","journal-title":"Yonsei Med J"},{"key":"1496_CR43","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1080\/00498254.2017.1282646","volume":"48","author":"ZE Tibbs","year":"2018","unstructured":"Tibbs ZE, Guidry AL, Falany JL, Kadlubar SA, Falany CN. A high frequency missense SULT1B1 allelic variant (L145V) selectively expressed in African descendants exhibits altered kinetic properties. Xenobiotica. 2018;48:79\u201388. https:\/\/doi.org\/10.1080\/00498254.2017.1282646.","journal-title":"Xenobiotica"},{"key":"1496_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10157-019-01816-4","volume":"24","author":"Y Kumagai","year":"2020","unstructured":"Kumagai Y, Sakaki M, Furihata K, et al. Dotinurad: a clinical pharmacokinetic study of a novel, selective urate reabsorption inhibitor in subjects with hepatic impairment. Clin Exp Nephrol. 2020;24:25\u201335. https:\/\/doi.org\/10.1007\/s10157-019-01816-4.","journal-title":"Clin Exp Nephrol"},{"key":"1496_CR45","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1002\/kjm2.12579","volume":"38","author":"MJ Huang","year":"2022","unstructured":"Huang MJ, Chen PL, Huang CS. Bilirubin metabolism and UDP-glucuronosyltransferase 1A1 variants in Asians: Pathogenic implications and therapeutic response. Kaohsiung J Med Sci. 2022;38:729\u201338. https:\/\/doi.org\/10.1002\/kjm2.12579.","journal-title":"Kaohsiung J Med Sci"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-025-01496-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-025-01496-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T13:05:36Z","timestamp":1764594336000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-025-01496-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":45,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1496"],"URL":"https:\/\/doi.org\/10.1007\/s40261-025-01496-x","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,19]]},"assertion":[{"value":"21 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Y. Liu and Q. Chen have received honoraria (investigator fees) from Eisai Co., Ltd. H. Sun is an employee of Eisai China Inc. C. Cai, K. Kawamura, R. Kokan, and M. Nomoto are employees of Eisai Co., Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"The protocol was approved by the ethics committee of Shanghai Xuhui Central Hospital (approval number 2022-002). The study was conducted in accordance with the Declaration of Helsinki and Chinese Good Clinical Practice guidelines and all applicable regulations. All study participants provided written informed consent. This study was registered at ClinicalTrials.gov under the identifier number NCT05278676.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval and Consent to Participate"}},{"value":"Written consent for publication was obtained from all study participants.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"The data that support the findings of this study are available from the corresponding author upon reasonable request.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"All analyses were conducted using standard software (SAS 9.4 and Phoenix WinNonlin\n                      TM\n                      8.3.5). No custom code was used in this study, so code availability is not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Conceptualization and methodology: Cuiyuan Cai, Kotomi Kawamura, Maiko Nomoto; investigation: Yun Liu, Qian Chen, Hui Sun, Rieko Kokan; formal analysis: Yun Liu, Qian Chen, Cuiyuan Cai, Maiko Nomoto; Writing\u2014original draft and writing\u2014review and editing: all authors. All authors read and approved the final version and agreed to submit the article for publication. All authors also confirm accountability for the accuracy and integrity of the work.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}